Tagged with Ranking

Global The world’s top 10 medical technology companies for 2022 according to Medical Product Outsourcing (MPO). Abbott leads the way, followed by Medtronic, J&J, and Siemens Healthineers. Recent PharmaBoardroom interviews with some of these companies’ leading executives include Hugo F. Villegas, SVP & President, Canada & Latin America at Medtronic, Eman…

Global Global biopharma is increasingly moving towards biologic medicines, which promise a greater impact on patient’s lives than the small-molecule drugs that preceded them, but which come with significant added costs and complexity. Against this backdrop, biologic drug developers are leaning evermore on experienced contract development and manufacturing organizations (CDMOs), of…

Global The top 20 pharmaceutical companies in the world for the past year, according to Pharmaceutical Executive’s latest annual rankings. Pfizer holds sway at the top of the leaderboard, with its BioNTech-partnered COVID-19 vaccine Comirnaty still generating an incredible USD 37.8 billion in 2022 and its COVID-19 antiviral Paxlovid adding a…

Europe The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain components, including manufacturing, to independent CDMOs. In Europe the CDMO market is expected to reach a revenue of nearly USD…

Thailand The top ten companies in the USD 6.9 billion Thai pharma market for 2021 ranked by market share, compiled by Thai banking firm Krungsti. Three of the featured firms – Mega Lifesciences, Better Pharma, and Berlin Pharma – are locals, while multinationals of the likes of AstraZeneca, Pfizer, and Novartis…

Global With the global market for generic drugs expected to reach USD 36.4 billion by 2027 and grow at a CAGR of 5.6 percent over the period 2020-2027, it is not surprising that a number of generics producers continue to rank among the world’s top pharma companies. A look at the…

Japan Japan is known for its cutting-edge technology, innovative products, and world-class healthcare system. The pharmaceutical industry in Japan is no exception, with many leading companies making significant contributions to global health and wellness. Read on for a rundown of the top 10 Japanese pharmaceutical companies (based on market capitalisation in…

LatAm A breakdown of the investments made by the pharmaceutical industry in clinical studies across the Latin American region. According to the US National Library of Medicine’s ClinicalTrials.gov, USD 1.1 billion were invested in 2019 with Mexico, Brazil and Argentina at the head of the LatAm countries where these investments were…

LatAm As selected by the Generics & Biosimilars Initiative (GABI), these are the top ten pharma companies ranked by turnover in Argentina, Brazil, Chile, Colombia, and Mexico for 2021. As the chart shows, the Argentinian and Brazilian Top Tens are dominated by domestic companies, while multinationals hold sway in Colombia and…

China The top 10 Chinese pharma companies for 2022, ranked by sales value and based on data from the latest Forbes Global 2000 ranking. Big conglomerates like Sinopharm, Shanghai Pharmaceuticals, and Jointown dominate the list, while other national champions in the midst of expanding their innovation efforts like Jiangsu Hengrui and…

Global COVID-19 vaccines and treatments continue to make headline news and bring in huge revenues for sponsor companies, but Pharma Exec’s 2022 Top 50 Companies ranking suggests that many non-COVID products are once more driving big gains. Against the backdrop of an increasingly fraught geopolitical climate and patent landscape, the next…

Global The Contract Development and Manufacturing Organisation (CDMO) industry has boomed in recent years, with Big Pharma increasingly focusing on its core business of R&D and outsourcing other elements of the supply chain, including manufacturing, to third-party CDMOs. Additionally, the global proliferation of biotechs – most of which lack the in-house…